Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea (uGC)

GSK said the FDA approved Blujepa (gepotidacin) as an oral treatment for uncomplicated urogenital gonorrhoea in adults and adolescents ≥12 years and ≥45 kg with limited or no alternative options, marking the first new antibiotic class for gonorrhoea in over three decades. Approval was supported by the phase III EAGLE‑1 trial (~600 patients) showing gepotidacin (two oral doses of 3,000 mg) was non‑inferior to intramuscular ceftriaxone plus oral azithromycin, with no serious drug‑related adverse events and mainly mild–moderate gastrointestinal side effects; gepotidacin was earlier approved this year for uncomplicated UTI after larger EAGLE‑2/3 studies. Given >600,000 US gonorrhoea cases in 2023, WHO/CDC antimicrobial‑resistance concerns and BARDA/DoD funding for development, the approval gives GSK an oral alternative to injectable standard‑of‑care for patients with contraindications or intolerance and bolsters its strategic positioning in anti‑infectives addressing AMR.

Analysis

GSK announced FDA approval of Blujepa (gepotidacin) as an oral treatment for uncomplicated urogenital gonorrhoea in adults and adolescents ≥12 years weighing ≥45 kg who have limited or no alternative options. The approval makes gepotidacin the first new antibiotic class for gonorrhoea in over three decades and follows an earlier FDA approval this year for uncomplicated urinary tract infection supported by the larger EAGLE‑2/3 programme.

Approval was supported by the EAGLE‑1 phase III trial (~600 patients) demonstrating non‑inferiority to intramuscular ceftriaxone (500 mg) plus oral azithromycin (1,000 mg) with gepotidacin dosed as two oral 3,000 mg doses; no serious drug‑related adverse events were observed and the most common reactions were mild–moderate gastrointestinal events. Gonorrhoea had over 600,000 reported US cases in 2023 and is identified by WHO and the CDC as a priority/urgent AMR threat, highlighting unmet need given reliance on injectable standard‑of‑care and absence of a licensed vaccine.

The programme’s partial funding from BARDA and the US Department of Defense underscores public‑sector interest and potential government procurement pathways, which may support commercialisation. Commercial uptake may be constrained initially by the restrictive label (patients with limited or no alternatives), potential guideline adoption timing, post‑market safety/resistance developments, and reimbursement dynamics despite clinical efficacy.

Key Decisions for Investors

• Consider a modest overweight or maintain position in GSK given the strategic pipeline benefit and positive phase III data, while sizing exposure cautiously because the current approval is limited to patients with limited or no alternatives
• Monitor prescription uptake, CDC/ID guideline endorsements, post‑marketing safety reports and Neisseria gonorrhoeae resistance surveillance over the next 6–12 months; material positive trends would justify increasing exposure
• Track BARDA/DoD contracting or commercial milestones as potential catalysts and be prepared to hedge near‑term downside (for example via options) if guideline adoption or reimbursement proves slower than anticipated